Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOG NASDAQ:GLSI NASDAQ:IOBT OTCMKTS:PVCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACOGAlpha Cognition$9.90+8.4%$9.69$3.75▼$11.54$146.26M2.7242,103 shs43,460 shsGLSIGreenwich LifeSciences$12.18+4.4%$10.29$8.06▼$16.50$156.01M1.6578,986 shs92,285 shsIOBTIO Biotech$1.81-4.2%$1.67$0.66▼$2.48$124.51M0.44597,670 shs358,055 shsPVCTProvectus Biopharmaceuticals$0.08+0.8%$0.08$0.04▼$0.15$33.62M0.57207,027 shs28,493 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACOGAlpha Cognition+8.43%+9.39%-8.33%+33.24%+989,999,900.00%GLSIGreenwich LifeSciences+4.37%+9.83%+15.45%+29.16%-11.16%IOBTIO Biotech-4.23%-18.47%+25.69%+81.00%+37.12%PVCTProvectus Biopharmaceuticals+1.00%-12.30%+6.61%-15.69%-9.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACOGAlpha Cognition1.6415 of 5 stars3.50.00.00.02.40.80.0GLSIGreenwich LifeSciences1.1874 of 5 stars3.51.00.00.00.01.70.0IOBTIO Biotech3.1978 of 5 stars3.73.00.00.03.02.50.6PVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACOGAlpha Cognition 3.00Buy$20.00102.02% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00220.20% UpsideIOBTIO Biotech 3.33Buy$9.33415.65% UpsidePVCTProvectus Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PVCT, IOBT, GLSI, and ACOG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ACOGAlpha CognitionHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACOGAlpha CognitionN/AN/AN/AN/A$2.59 per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AIOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/APVCTProvectus Biopharmaceuticals$620K54.64N/AN/A($0.01) per share-8.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACOGAlpha Cognition-$14.64M-$1.20N/A∞N/AN/A-65.83%-48.21%8/14/2025 (Confirmed)GLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/13/2025 (Estimated)IOBTIO Biotech-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)PVCTProvectus Biopharmaceuticals-$4.76MN/A0.00∞N/A-815.81%N/A-644.80%8/11/2025 (Estimated)Latest PVCT, IOBT, GLSI, and ACOG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACOGAlpha Cognition-$0.84N/AN/AN/A$2.32 millionN/A8/13/2025N/AGLSIGreenwich LifeSciences-$0.24N/AN/AN/AN/AN/A8/12/2025Q2 2025IOBTIO Biotech-$0.35N/AN/AN/AN/AN/A5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/15/2025Q1 2025ACOGAlpha Cognition-$0.58-$0.20+$0.38-$0.13$0.50 million$2.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACOGAlpha CognitionN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/APVCTProvectus BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACOGAlpha CognitionN/A17.1416.83GLSIGreenwich LifeSciencesN/A1.911.91IOBTIO BiotechN/A2.322.32PVCTProvectus BiopharmaceuticalsN/A0.110.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACOGAlpha CognitionN/AGLSIGreenwich LifeSciences4.16%IOBTIO Biotech54.76%PVCTProvectus Biopharmaceuticals0.05%Insider OwnershipCompanyInsider OwnershipACOGAlpha Cognition14.00%GLSIGreenwich LifeSciences51.67%IOBTIO Biotech4.80%PVCTProvectus Biopharmaceuticals14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACOGAlpha CognitionN/A16.02 million13.78 millionN/AGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableIOBTIO Biotech30N/AN/ANot OptionablePVCTProvectus Biopharmaceuticals4420.28 million358.50 millionNot OptionablePVCT, IOBT, GLSI, and ACOG HeadlinesRecent News About These CompaniesProvectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Increase in Short InterestAugust 6 at 2:53 AM | americanbankingnews.comProvectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck Cancer - MorningstarJune 27, 2025 | morningstar.comMProvectus Biopharmaceuticals Announces Publication of Moffitt Cancer Center Research on PV-10 for Head and Neck CancerJune 26, 2025 | globenewswire.comProvectus Biopharmaceuticals Announces Investor Webinar for 2025 Annual Meeting of StockholdersJune 9, 2025 | globenewswire.comCroatia's Provectus Capital Partners opens office in RomaniaApril 24, 2025 | seenews.comSProvectus announces $3M seed financing round for VisiRoseJanuary 14, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus’s Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | markets.businessinsider.comProvectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye DrugsJanuary 14, 2025 | globenewswire.comProvectus launches VisiRose, Provectus’s Founded Entity for pharmaceutical-grade rose bengal sodium-based treatments in ophthalmologyDecember 13, 2024 | pharmabiz.comPProvectus announces the launch of VisiRoseDecember 12, 2024 | markets.businessinsider.comVisiRose Introduces Revolutionary Therapy for Severe Eye InfectionsDecember 10, 2024 | miamiherald.comMProvectus Pharmaceuticals Aligns Leadership with Equity GrantsDecember 6, 2024 | markets.businessinsider.comProvectus Pharmaceuticals to Reveal Key 2024 UpdatesNovember 15, 2024 | markets.businessinsider.comProvectus Biopharmaceuticals, Inc. (PVCT) Q4 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comProvectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference CallOctober 24, 2024 | manilatimes.netMProvectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference CallOctober 10, 2024 | globenewswire.comProvectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual MeetingMay 21, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual MeetingMay 14, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor CancersApril 18, 2024 | finance.yahoo.comProvectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value CreationApril 16, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePVCT, IOBT, GLSI, and ACOG Company DescriptionsAlpha Cognition NASDAQ:ACOG$9.90 +0.77 (+8.43%) As of 08/8/2025 04:00 PM EasternAlpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.Greenwich LifeSciences NASDAQ:GLSI$12.18 +0.51 (+4.37%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$12.35 +0.17 (+1.40%) As of 08/8/2025 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.IO Biotech NASDAQ:IOBT$1.81 -0.08 (-4.23%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$1.81 0.00 (0.00%) As of 08/8/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Provectus Biopharmaceuticals OTCMKTS:PVCT$0.08 +0.00 (+0.75%) As of 08/8/2025 03:59 PM EasternProvectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adult solid tumor cancers, as well as refractory and relapsed pediatric, and other blood cancers comprising leukemias; PV-10 for the treatment of relapsed and refractory pediatric solid tumor cancers; and other formulations for the treatment of cutaneous canine cancers and healing of full-thickness cutaneous wounds. In addition, the company develops oral and intranasal formulations for the treatment of severe acute respiratory syndrome coronavirus 2; gram-positive and gram-negative bacterial infections; oral bacterial infections; and fungal infections, as well as vertebrate development, wound healing, and tissue regrowth. It has collaboration agreement with Bascom Palmer Eye Institute; and University of Miami. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was founded in 2002 and is based in Knoxville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
